TribLIVE

| Business

 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck, Pfizer sue to block proposed version of AzaSite

Email Newsletters

Click here to sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

MRK $47.80 -$0.15

PFE $29.16 +$0.07

MYL $31.54 -$0.14

at close on MONDAY

By Bloomberg News
Tuesday, June 18, 2013, 12:01 a.m.
 

Merck & Co. and Pfizer Inc. sued generic drugmaker Mylan Pharmaceuticals Inc. to block it from selling a copy of AzaSite, an antibiotic eye solution for fighting bacterial conjunctivitis.

Mylan told Pfizer, Merck and InSite Vision Inc. on May 1 that it sought Food and Drug Administration approval to sell a generic version of AzaSite, according to a lawsuit filed on Friday in federal court in Trenton, N.J. The complaint asks a judge to prevent Mylan from entering the market before the patents expire. One ends in 2018, and the other three expire in 2019, according to the FDA website.

Subscribe today! Click here for our subscription offers.

 

 


Show commenting policy

Most-Read Business Headlines

  1. Alcoa putting $60M into Upper Burrell tech center expansion
  2. Fifth Third Bank selling Pittsburgh branches to First National
  3. Pa. business interests decry EPA ozone proposal as economic albatross
  4. PPG’s new CEO to push organic growth with existing clients
  5. Housing bright spot as Beige Book survey shows Pittsburgh region’s growth slight
  6. Just Mayo has egg industry in a panic, emails show
  7. Coal company, UMW settle suit over use of non-union workers
  8. Consumer Financial Protection Bureau gives alternative to customer service frustrations
  9. Steelworkers union says ATI talks to resume
  10. Macy’s prepares outlet stores
  11. ModCloth gets physical